Novo Nordisk today joined Eli Lilly and Co., AstraZeneca, Sanofi, Novartis, and United Therapeutics in imposing conditions on provision of 340B pricing on products dispensed by contract pharmacies. Today’s announcement means all three U.S. domestic suppliers of insulin (Lilly, Sanofi, and Novo Nordisk) have adopted such policies.
Novo Nordisk Will Cease 340B Pricing for Hospital Contract Pharmacies on Jan. 1
Drug manufacturer Novo Nordisk announced late today that beginning Jan. 1 it “will no longer facilitate ‘bill-to/ship-to’ distribution of 340B product to a contract pharmacy of any of the six ‘hospital’ covered entity types.”
The U.S. Health Resources and Services Administration (HRSA) told 340B Report it “is aware of Novo Nordisk’s plan and is in the process of reviewing and determining next steps.”
.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
